VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 1,689,232 shares, an increase of 250.0% from the December 15th total of 482,674 shares. Based on an average trading volume of 25,987,592 shares, the days-to-cover ratio is currently 0.1 days. Approximately 5.2% of the company’s shares are short sold. Approximately 5.2% of the company’s shares are short sold. Based on an average trading volume of 25,987,592 shares, the days-to-cover ratio is currently 0.1 days.

Analysts Set New Price Targets

Several research analysts have recently issued reports on VYNE shares. Weiss Ratings restated a “sell (e+)” rating on shares of VYNE Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded VYNE Therapeutics to a “sell” rating in a report on Saturday, December 20th. Three investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $4.50.

VYNE Therapeutics Trading Up 0.2%

Shares of VYNE opened at $0.57 on Thursday. The firm’s 50 day moving average is $0.45 and its 200-day moving average is $0.54. The stock has a market capitalization of $18.86 million, a PE ratio of -0.73 and a beta of 1.95. VYNE Therapeutics has a 12 month low of $0.28 and a 12 month high of $3.08.

VYNE Therapeutics (NASDAQ:VYNE) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. VYNE Therapeutics had a negative return on equity of 80.84% and a negative net margin of 6,425.19%.The business had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.13 million. Equities research analysts predict that VYNE Therapeutics will post -0.97 earnings per share for the current fiscal year.

Institutional Investors Weigh In On VYNE Therapeutics

Several institutional investors have recently added to or reduced their stakes in VYNE. Baker BROS. Advisors LP purchased a new stake in shares of VYNE Therapeutics in the third quarter worth about $285,000. Kennedy Capital Management LLC bought a new position in shares of VYNE Therapeutics during the 2nd quarter valued at $942,000. Shay Capital LLC bought a new position in VYNE Therapeutics during the 3rd quarter worth approximately $165,000. Adage Capital Partners GP L.L.C. increased its stake in shares of VYNE Therapeutics by 87.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock worth $1,063,000 after buying an additional 300,000 shares during the period. Finally, Two Sigma Investments LP purchased a new stake in shares of VYNE Therapeutics during the third quarter worth about $74,000. 83.78% of the stock is owned by hedge funds and other institutional investors.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.